ARK Investment Management LLC Sells 422,788 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

ARK Investment Management LLC decreased its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,346,398 shares of the company’s stock after selling 422,788 shares during the period. Recursion Pharmaceuticals comprises about 1.8% of ARK Investment Management LLC’s holdings, making the stock its 16th largest holding. ARK Investment Management LLC owned about 8.28% of Recursion Pharmaceuticals worth $218,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. IFP Advisors Inc lifted its stake in Recursion Pharmaceuticals by 170.4% in the 4th quarter. IFP Advisors Inc now owns 11,831 shares of the company’s stock valued at $80,000 after purchasing an additional 7,455 shares during the last quarter. Colonial River Investments LLC bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at $68,000. Handelsbanken Fonder AB raised its stake in shares of Recursion Pharmaceuticals by 5.9% during the fourth quarter. Handelsbanken Fonder AB now owns 73,600 shares of the company’s stock valued at $498,000 after acquiring an additional 4,100 shares during the last quarter. Private Advisor Group LLC raised its stake in shares of Recursion Pharmaceuticals by 103.8% during the fourth quarter. Private Advisor Group LLC now owns 31,427 shares of the company’s stock valued at $212,000 after acquiring an additional 16,008 shares during the last quarter. Finally, Global Retirement Partners LLC raised its stake in shares of Recursion Pharmaceuticals by 31.5% during the fourth quarter. Global Retirement Partners LLC now owns 31,297 shares of the company’s stock valued at $212,000 after acquiring an additional 7,500 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 9.6 %

RXRX opened at $8.14 on Wednesday. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.60 and a twelve month high of $15.74. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a fifty day moving average of $7.61 and a 200-day moving average of $7.06. The stock has a market cap of $3.18 billion, a PE ratio of -5.32 and a beta of 0.86.

Analyst Ratings Changes

RXRX has been the subject of several analyst reports. KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.